Início › Mieloma Múltiplo › Connecticut
Ensaios clínicos de Mieloma Múltiplo em Connecticut
18 estudos para Mieloma Múltiplo estão buscando participantes em locais em Connecticut.
Cidades em Connecticut
Texto oficial do estudo (Inglês)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07391657A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University of Connecticut, Farmington
- Yale New Haven Hospital, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Connecticut Health Center, Farmington
- Yale Cancer Center, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07258511A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Yale University School Of Medicine, New Haven
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06500884A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Connecticut Health Center, Farmington
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07518186Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center - Guilford, Guilford
- Yale University, New Haven
- e mais 1
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06465316TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Saint Vincent's Medical Center (SVMC), Bridgeport
- Hartford Hospital, Hartford
- Midstate Medical Center (MSMC), Meriden
- e mais 4
RecrutandoFase 2
Idades 12 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT02693535A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Smilow Cancer Center At Yale-New Haven /ID# 272447, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06953960Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Yale University, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT07555938A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Yale New Haven Hospital-Smilow Cancer Center, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06988488A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Norwich
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT07227311Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
- e mais 11
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 14 de ago. de 2026 · NCT07764978Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
- e mais 11
RecrutandoFase 3
Todas as idades · Todos os sexos · Atualizado em 10 de jun. de 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Yale New Haven Hospital, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 4 de jun. de 2026 · NCT05243797Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- Yale University, New Haven
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 13 de mai. de 2026 · NCT06993675A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Yale Cancer Center, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de mar. de 2026 · NCT06153251Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.